AI in Healthcare: New Treatments & Discovery

Recursion Pharmaceuticals’ AI-Driven FAP Treatment Shows Promise, Faces Regulatory Questions

A new oral medication from Recursion Pharmaceuticals is demonstrating important reductions in Familial Adenomatous Polyposis (FAP) polyps, but a health policy expert is raising concerns about the pace of regulatory approval adn the lack of emphasis on potential cost savings. The treatment, developed using artificial intelligence, is being hailed as “promising” by the scientific community.

Recursion Pharmaceuticals announced the positive results on December 11, 2025, offering hope for the over 50,000 individuals living with this challenging genetic condition.The findings suggest a substantial and sustained decrease in polyp formation, a key indicator of disease progression.

Did you know? – FAP is caused by a mutation in the APC gene, leading to the development of hundreds or thousands of polyps in the colon and rectum. Without treatment, nearly all individuals with FAP develop colorectal cancer.

The High Cost of FAP

Currently,managing FAP is a lifelong and expensive undertaking. According to available data, early detection strategies can cost upwards of $10,000, while late detection can exceed $37,000. The potential for FAP to develop into metastatic colorectal cancer further escalates costs, with treatment perhaps reaching $300,000.

“the cost to society from FAP easily exceeds $1 billion per year, or more than $15 billion on a present value basis,” noted a health policy analyst. This staggering figure underscores the urgent need for more effective and affordable treatments.

Calls for Expedited Approval

Despite the encouraging results, one observer expressed disappointment with the company’s communication regarding the treatment’s economic impact. “I was disappointed not to see/here any reference to the savings of the cost to society from this treatment and a vague reference to working with the FDA in the frist half of 2026,” the analyst stated. “Quite frankly, the urgency seemed to be lacking.”

The analyst argues that sufficient data on both efficacy and safety now exists to warrant a broader submission of the medication, while continuing to refine dosage levels and identify optimal patient populations. Delaying access,they contend,will only lead to increased suffering and financial burden.

Pro tip: – Regular colonoscopies are crucial for individuals with FAP, even with new treatments.Thes screenings help detect and remove polyps, reducing cancer risk.

A Personal Stake in the Fight

The call for swift action comes from Steve Zecola, a health policy consultant who has firsthand experience with chronic illness. Zecola, diagnosed with Parkinson’s disease 23 years ago, sold his technology business to focus on health-related advocacy and research. He has since dedicated his time to consulting and teaching, alongside maintaining a rigorous exercise regimen.

Zecola’s personal journey underscores the importance of innovation and accessibility in healthcare, and his perspective adds weight to the argument for accelerating the approval process for this potentially life-changing treatment.

The future of FAP treatment hinges on a swift and decisive response from regulatory bodies,balancing the need for thorough evaluation with the imperative to deliver relief to those who desperately need it.

Reader question: – What factors do you think should be prioritized when balancing the speed of drug approval with ensuring patient safety? Share your thoughts.

Why, Who, What, and How did it end?

Why: The article focuses on the need for faster regulatory approval of Recursion Pharmaceuticals’ new oral medication for Familial adenomatous Polyposis (FAP) due to the high cost and significant burden of the disease. A health policy consultant is also concerned about the lack of emphasis on potential cost savings.

Who: The key players are Recursion Pharmaceuticals (developer of the medication), a